search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Clinical and histologic effect of transrectal intraprostatic injections with botulinum toxin A in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia.


- candidate number2199
- NTR NumberNTR749
- ISRCTNISRCTN42633050
- Date ISRCTN created22-nov-2006
- date ISRCTN requested8-nov-2006
- Date Registered NTR7-aug-2006
- Secondary IDsN/A 
- Public TitleClinical and histologic effect of transrectal intraprostatic injections with botulinum toxin A in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia.
- Scientific TitleClinical and histologic effect of transrectal intraprostatic injections with botulinum toxin A in patients with lower urinary tract symptoms caused by benign prostatic hyperplasia.
- ACRONYMBOP1
- hypothesisBotulinum toxin type A injection of the prostate causes relaxation and cellular apoptosis and by this way will relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia.
- Healt Condition(s) or Problem(s) studiedBenign prostatic hyperplasia
- Inclusion criteria1. Age > 55
2. Signed informed consent
3. LUTS with IPSS (international prostatic symptom score)
> 7
4. Insufficient respons to oral medication
5. Prostatic volume 30-50 ml
6. Urodynamic infravesical obstruction > grade II according to Schafer
7. Willing and able to fill out questionnaires and voiding diaries
8. Willing and able to attend proposed investigations
- Exclusion criteria1. Neuropathic bladder dysfunction
2. Prostatic carcinoma
3. Coagulation disorder
4. Urinary tract infection
5. Bladder calculus
6. Postrenal renal insufficiency
7. Myopathic disorder
8. Anatomical defects preventing transrectal approach
- mec approval receivedno
- multicenter trialno
- randomisedno
- group[default]
- Type-
- Studytypeintervention
- planned startdate 1-jan-2007
- planned closingdate30-jun-2008
- Target number of participants20
- InterventionsTransrectal intraprostatic injection with botulinum toxin type A
- Primary outcomeSymptom relief according to the International Prostatic Symptom Score(IPSS)
- Secondary outcome1. Urodynamic obstruction (according to Schafer)
2. Post void residual
3. Decrease in prostate volume
4. Histologic change after 1 month
5. PSA change
6. Other treatment needed
- Timepoints
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESMD.PhD. L.M.O. Kort, de
- CONTACT for SCIENTIFIC QUERIESMD.PhD. L.M.O. Kort, de
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
- PublicationsN/A
- Brief summaryRationale:
The standard treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, not responding to medication, is transurethral prostatic resection. This is an invasive procedure requiring general or regional anestesia. Intraprostatic injection of Botox causes relaxation of smooth muscle tissue and causes cellular apoptosis. Therefore it is possibly effective for treatment of benign prostatic hyperplasia. Transrectal prostatic injection is minimally invasive and can be performed without anestesia in the outpatient clinic.
Objective:
To determine the subjective effect on lower urinary tract symptoms and to determine objective urodynamic and histologic changes after intraprostatic botulinum toxin injection.
Study design:
Prospective.
Study population:
Male patients with lower urinary tract symptoms due to benign prostatic hyperplasia, not responding to medication.
Intervention:
Transrectal injection of botulinum toxin into the prostate.
Main study parameters/endpoints:
Symptom relief (IPSS).
Urodynamic obstruction (according to Schafer)
Post void residual
Decrease of prostate volume
Histologic changes after 1 month.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
At least 8 visits to the outpatient clinic are necessary. Four urodynamic studies will be performed (in total 4 hours). Patients will be asked to fill out questionnaires and voiding diaries with every visit. There is a risk for prostatitis and a risk for hemorrage due to the prostatic biopsy and after the intraprostatic injection. Furthermore there is a risk for side effects of the botulinum toxin like allergy (infrequently), aritmia and respiratory problems in case of overdose.
- Main changes (audit trail)
- RECORD7-aug-2006 - 4-dec-2006


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl